A randomized trial of pivanex [AN 9] plus docetaxel or docetaxel monotherapy in patients with chemotherapy resistant advanced non-small cell carcinoma of the lung (NSCLC)

Trial Profile

A randomized trial of pivanex [AN 9] plus docetaxel or docetaxel monotherapy in patients with chemotherapy resistant advanced non-small cell carcinoma of the lung (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2005

At a glance

  • Drugs AN 9; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top